![Page 1: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/1.jpg)
Novel Tuberculosis Drugs of the 21st Century
N
NO2N O N O
Philip Bentley
October 7, 2009
N
O
OCF3
PA-824
Br NOH
TMC207
![Page 2: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/2.jpg)
Introduction
Tuberculosis (TB)-
“An infectious disease of humans and animals caused by the
tubercle bacillus and characterized by the formation of tubercles on the lungs and other tissues of the body, often tubercles on the lungs and other tissues of the body, often developing long after the initial infection.”
Tubercle bacillus-“A rod- shaped aerobic bacterium (Mycobacterium
tuberculosis) that causes tuberculosis.”
2
Pickett, J.P., et al., Eds. The American Heritage College dictionary, 4th ed.; Houghton Mifflin Company: Boston, MA, 2002; p 1477.
Image taken from: Jabado, N.; Gros, P. Nature 2005, 434, (7034), 709-711.
![Page 3: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/3.jpg)
An Ancient Disease
“Consumption” and “white plague”
“Hippocrates, the ancient Greek physician, noted that ‘phthisis’ (consumption) was the most widespread ‘phthisis’ (consumption) was the most widespread and fatal disease of his time.” (>2,000 yrs ago)
Found in skulls and spines of Egyptian mummies (4,000 yrs old)
3Nobel Prize Website: http://nobelprize.org/educational_games/medicine/tuberculosis/readmore.html (accessed September 15, 2009).
![Page 4: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/4.jpg)
Today
As of March 24, 2009 (World TB Day)
9.27 million NEW cases in 2007
4Donald, P. R.; van Helden, P. D. N. Engl. J. Med. 2009, 360, (23), 2393-2395.
22 Asian and African countries account for 80% of global TB
Cost to diagnose and treat 1.4 million cases
in high burden regions
$16.9 billion
![Page 5: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/5.jpg)
Pathogenesis of TB
Mode of Infection
Ingestion (intestines)Consumption of contaminated milk
Inhalation (lungs)
5
Reddy, C.A. Veterinary Pathogenic Bacteriology, Department of Microbiology & Molecular Genetics: Michigan State University, 2008, pp194.Jabado, N.; Gros, P. Nature 2005, 434, (7034), 709-711.
Inhalation (lungs)Intake of airborne pathogens
Deposited in Lymph nodes
(~2 weeks)
![Page 6: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/6.jpg)
Pathogenesis of TB
Regional Lymph nodes
Bloodstream
A few Days
1-2 weeks
6
Reddy, C.A. Veterinary Pathogenic Bacteriology, Department of Microbiology & Molecular Genetics: Michigan State University, 2008, pp194.Jabado, N.; Gros, P. Nature 2005, 434, (7034), 709-711.
Also, latent forms
(1/3 population)
Throughout Body
Cell-mediated immuneResponse
infection progressesto Tuberculosis
Organism uptakenby activatedmacrophage
![Page 7: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/7.jpg)
Main Challenge
7Image from: http://www3.niaid.nih.gov/topics/tuberculosis/Research/basicResearch/biology_cell.htm
Normal bacteria cell wall TB cell wall
Vs.
![Page 8: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/8.jpg)
Main Challenge
O
(CH2)23CH3
(CH2)17
OH
(CH2)10CH3(CH2)17
Trehalose =
8
Tonge, P. J. Nat. Struct. Mol. Biol. 2000, 7, 94-96.Yuan, Y.; Barry, C. E., III Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 12828-12833.Image from: http://www3.niaid.nih.gov/topics/tuberculosis/Research/basicResearch/biology_cell.htm
TB cell wall
R =
O
(CH2)23CH3
(CH2)17
OH
(CH2)10CH3(CH2)17
O
(CH2)23CH3
(CH2)17
OH
(CH2)10CH3(CH2)17
H3C OCH3
O
(CH2)23CH3
(CH2)17
OH
(CH2)10CH3(CH2)17
H3C O
O
(CH2)23CH3
(CH2)17
OH
(CH2)10CH3(CH2)17
H3C OH
![Page 9: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/9.jpg)
Mycolyl Transfer Mechanism
9Ronning, D. R.; Klabunde, T.; Besra, G. S.; Vissa, V. D.; Belisle, J. T.; Sacchettini, J. C. Nat. Struct.
Biol. 2000, 7, 141-146.
ag85C protein
![Page 10: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/10.jpg)
Strides Towards a Cure
Nobel Prizes Awarded inPhysiology and Medicine
Robert Koch- 1905Discovery of Mycobacterium
Nobel Prize Website: http://nobelprize.org/educational_games/medicine/tuberculosis/readmore.html (accessed September 15, 2009).
Discovery of Mycobacterium
tuberculosis in 1882
Selman Waksman- 1952 Isolated active antibiotic from
Streptomyces griseus in 1943
10
![Page 11: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/11.jpg)
History of Drug Therapy
Alkaline mineral water, mercury, antimony, cod-liver oil, copper salts
Roman physicians recommended Bathing in human urine, eating wolf liver, and drinking elephant blood
Streptomycin (1943)
OH
OHO
HO NO
H3C
HO
NH2
NH2
OHC
11Borchardt, J.K. Drug News Perspect. 2002, 15, (8), 535-542.
Streptomycin (1943)Intravenous administration
First reported TB resistance (1947)
Para-aminosalicylic acid (1949)Prevented TB resistance
Need for long term use
Streptomycin
OHO
N
HO
O
NH2
NH2O
HO
HO
HONH
CH3
![Page 12: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/12.jpg)
History of Drug Therapy
Isoniazid (1952)Prodrug: Inhibits mycolic acid synthesis
Prevents latent to active TB N
HNO
NH2
Isoniazid
12
Rouche Phamaceuticals in the U.S.: About US. http://www.rocheusa.com/about/history.html (accessed Oct 4, 2009).Timmins, G. S.; Deretic, V. Mol. Microbiol. 2006, 62, 1220-1227.Borchardt, J.K. Drug News Perspect. 2002, 15, (8), 535-542.
Pyrazinamide (1954)Mechanism of action uncertain
Disrupts plasma membrane?
Disrupts energy metabolism?
![Page 13: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/13.jpg)
History of Drug Therapy
Ethambutol (1962)inhibits the synthesis of arabinogalactan
13
Rifampin (rifampicin) (1965)Inhibits RNA synthesis
Can eliminate dormant bacteria
O
OH
OH
NH
N
OH
O
O
N
O
OH
HO
O
N
O
O
Rifampin
Belanger, A. E.; Besra, G. S.; Ford, M. E.; Mikusova, K.; Belisle, J. T.; Brennan, P. J.; Inamine, J. M. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 11919-11924.Tonge, P. J. Nat. Struct. Mol. Biol. 2000, 7, 94-96.Borchardt, J.K. Drug News Perspect. 2002, 15, (8), 535-542.
![Page 14: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/14.jpg)
Combination Drug Therapy
Isoniazid and rifampingreatly decrease TB chance of survival
Isoniazid, rifampin, and pyrazinamide (Aventis: Rifater)shortened drug therapy
14Borchardt, J.K. Drug News Perspect. 2002, 15, (8), 535-542.
Isoniazid, rifampin, pyrazinamide, and ethambutolif resistant to isoniazid
Isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin
if resistant to both isoniazid and rifampin
![Page 15: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/15.jpg)
Summary of the Drug Regime
O
OH
NH
N
OH
O
N
OH
HO
O
O
O
15Borchardt, J.K. Drug News Perspect. 2002, 15, (8), 535-542.
N
N
O
NH2
Pyrazinamide
OHOO
N
Rifampin
![Page 16: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/16.jpg)
TB in the United States
22000
24000
26000
28000
30000# o
f P
ers
on
s I
nfe
cte
dTB Case Notifications (USA)
16
Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009 (Publication no. WHO/HTM/TB/2009.411.). Geneva: World Health Organization, 2009.Weis, S. E.; Slocum, P. C.; Blais, F. X.; King, B. ; Nunn, M.; Matney, G. B.; Gomez, E.; Foresman, B. H. N. Engl. J. Med. 1994, 330, 17), 1179-1184.
10000
12000
14000
16000
18000
20000
1975 1980 1985 1990 1995 2000 2005 2010
# o
f P
ers
on
s I
nfe
cte
d
Year
![Page 17: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/17.jpg)
Multi Drug Resistance (MDR)
17
Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009 (Publication no. WHO/HTM/TB/2009.411.). Geneva: World Health Organization, 2009.Donald, P. R.; van Helden, P. D. N. Engl. J. Med. 2009, 360, (23), 2393-2395.
![Page 18: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/18.jpg)
Need for 21st Century Drugs
Development of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains
(Not a single new compound since 1965)
Help reduce cost of MDR treatment
($15,000 for a 2 year treatment course)
Minimize fatalities
(30 million claimed btw 2000 and 2020)
18Borchardt, J.K. Drug News Perspect. 2002, 15, (8), 535-542.
![Page 19: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/19.jpg)
Drugs with Promising Results
N
NO2N O
O
OCF3
19
PA-824
N
Br NOH
O
TMC207
![Page 20: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/20.jpg)
Clinical Trial Phases
Phase of Clinical Trial
Number ofPatients
What they test
Preclinical N.A.In-vivo (Animal)
and in-vitro
Metabolic and pharmacologic
20
Phase I 20-30Metabolic and pharmacologic
properties
Phase II >100Test drug effectiveness &
Side effects and risks
Phase III 100s-1000sEfficacy, safety, benefit to risk
Gain FDA approval
Phase IV --- Long term effects
National Marrow Donor Program: What is a Clinical Trial? http://www.marrow.org/PATIENT/Undrstnd_Disease_Treat/Undrstnd_Treat_Opt/Lrn_Clinical_Trials/What_is_a_Clinical_Trial/index.html (accessed Oct 1, 2009).
![Page 21: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/21.jpg)
PA- 824
Phase II
No cross-resistance
Potentially inhibits drug-sensitive and drug-resistant strains
N
NO2N O
O
OCF3
resistant strains
In vitro activity against non-replicating TB
Unique mechanism of action
Inhibits TB cell wall mycolic acid synthesis
Pro-drug metabolized by TB
21
Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Krelswirth, B. N.; Barry, C. E.; Baker, W. R. Nature 2000, 405, (6789), 962-966.
![Page 22: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/22.jpg)
Synthesis of PA- 824
22Baker, W. R.; Cai, S.; Keeler, E. L. 96-US10904, 9701562, 19960625, 1997.
TBAF = N
F
![Page 23: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/23.jpg)
Synthesis of PA- 824
23Baker, W. R.; Cai, S.; Keeler, E. L. 96-US10904, 9701562, 19960625, 1997.
![Page 24: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/24.jpg)
PA- 824: Activity Against MDR TB
Drug Resistance MIC90 (µµµµg/ ml)
[PA-824]
MIC90 (µµµµg/ ml)
[isoniazid]
Drug susceptible strains 0.015 to 0.25 0.03 to 0.06
R 0.03 0.03
I, R 0.03
24
Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Krelswirth, B. N.; Barry, C. E.; Baker, W. R. Nature 2000, 405, (6789), 962-966.
I, R, E 0.03
I, S, E 0.25
I, R, S, E 0.03
I, R, E, P 0.06
I, S, E, P 0.25
I= isoniazid; R= rifampin; E= ethambutol; S= streptomycin; P= pyrazinamide
![Page 25: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/25.jpg)
Activity Against Non- Replicating TB
4.5
5
5.5
6
Activity on Non-Replicating TBControl PA-824 Isoniazid
Drug anaerobic No drug, aerobic
25
Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Krelswirth, B. N.; Barry, C. E.; Baker, W. R. Nature 2000, 405, (6789), 962-966.
1
1.5
2
2.5
3
3.5
4
-7 -5 -3 -1 1 3 5 7
Lo
g10
CF
U
Time (days)
0-7 1 2 4 7
![Page 26: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/26.jpg)
PA- 824: Mechanisms of Action
Two suggested mechanisms
Disruption of the mycolic acids of the TB cell envelope
Yuan, Y.; Zhu, Y.; Crane, D. D.; Barry, C. E., III, Mol. Microbiol. 1998, 29, (6), 1449-1458.Singh, R.; Manjunatha, U.; Boshoff, H. I. M.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E., III Science 2008, 322, (5906), 1392-1395.
26
Intracellular NO release
via a deazaflavin-dependent nitroreductase (Ddn) and the reduced form of cofactor F420
![Page 27: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/27.jpg)
PA- 824: Mechanisms of Action
2
3
�
�
27
Yuan, Y.; Zhu, Y.; Crane, D. D.; Barry, C. E., III, Mol. Microbiol. 1998, 29, (6), 1449-1458.Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Krelswirth, B. N.; Barry, C. E.; Baker, W. R. Nature 2000, 405, (6789), 962-966.
2
3
![Page 28: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/28.jpg)
PA- 824: Mechanisms of Action
Activity as a Prodrug
Little mycolic acid repair
28
Singh, R.; Manjunatha, U.; Boshoff, H. I. M.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E., III Science 2008, 322, (5906), 1392-1395.
![Page 29: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/29.jpg)
N
NN
O
R
O
Oreduction
H
N
NN
O
R
O
HO
N
NN
O
R
O
HO
N
NN
O
O
O
protonation
4
5
N
NO
NOH
O
hydrolysis
N
NN
OHO
reduction
N
R
N
NO
R
N
O
HO
5a
6a
29
Singh, R.; Manjunatha, U.; Boshoff, H. I. M.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E., III Science 2008, 322, (5906), 1392-1395.
N
R
N
NO
R
O
N
O
H
5b
6b
N
R
N
H2NO
R
reduction
5c
6c
![Page 30: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/30.jpg)
PA- 824: Mechanisms of Action
Deazaflavin- dependent nitroreductase (Ddn)
AND
Singh, R.; Manjunatha, U.; Boshoff, H. I. M.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E., III Science 2008, 322, (5906), 1392-1395.
30
![Page 31: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/31.jpg)
OPC- 67683
Completed Phase II
No cross-resistance
Inhibits drug-sensitive and drug-resistant strains
Similar mechanism of action to PA- 824
O
OCF3
N
O
O
N
NNO2
31Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. PLoS Med. 2006, 3, (11), 2131-2144.
Similar mechanism of action to PA- 824
Inhibits TB cell wall mycolic acid synthesis
Pro-drug metabolized by TB
Decreased time on drug regime
High efficacy in immunocompromised micesuggesting treatment for TB/HIV patients
![Page 32: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/32.jpg)
Synthesis of OPC- 67683
NHN
O2N
Cl
+Et3N, AcOEt,
60-65 oC, 6 h
87%
OO
O
K2CO3, MeOH,r.t., 2 h97%
7 8
NN
O2N
Cl
OOH
O
NO2
NN
O2N
Cl
OHOH
32Sasaki, H.; Haraguchi, Y.; Itotani, M.; Kuroda, H.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Matsumoto, M.; Komatsu, M.; Tsubouchi, H. J. Med. Chem. 2006, 49, (26), 7854-7860.
O
NO2
1.) MsCl, py., <15 oC, 2 h
2.) DBU, AcOEt, r.t., 2 h
(75% for 2 steps)8
9
NN
O2N
Cl
O
![Page 33: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/33.jpg)
Synthesis of OPC- 67683
33Sasaki, H.; Haraguchi, Y.; Itotani, M.; Kuroda, H.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Matsumoto, M.; Komatsu, M.; Tsubouchi, H. J. Med. Chem. 2006, 49, (26), 7854-7860.
![Page 34: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/34.jpg)
Synthesis of OPC- 67683
34Sasaki, H.; Haraguchi, Y.; Itotani, M.; Kuroda, H.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Matsumoto, M.; Komatsu, M.; Tsubouchi, H. J. Med. Chem. 2006, 49, (26), 7854-7860.
![Page 35: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/35.jpg)
TB Strain (MIC90) MIC90 (µµµµg/ml)
rifampin- susceptible (0.288: 24x) 0.01248
isoniazid- susceptible (0.099: 8x) 0.01194
OPC- 67683: Pharmacokinetics
isoniazid- susceptible (0.099: 8x) 0.01194
ethambutol- susceptible (3.636: 303x) 0.01213
streptomycin- susceptible (2.938: 244x) 0.01203
Average (0.012)
35Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. PLoS Med. 2006, 3, (11), 2131-2144.
![Page 36: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/36.jpg)
OPC- 67683: Pharmacokinetics
TB Strain (MIC90) MIC90 (µµµµg/ml)
rifampin- susceptible 0.01248
rifampin- resistant 0.01221
isoniazid- susceptible 0.01194isoniazid- susceptible 0.01194
isoniazid- resistant 0.01279
ethambutol- susceptible 0.01213
ethambutol- resistant 0.01341
streptomycin- susceptible 0.01203
streptomycin- resistant 0.0134
36Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. PLoS Med. 2006, 3, (11), 2131-2144.
![Page 37: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/37.jpg)
4
5
6
7
CF
U
ORP RIEP
OPC- 67683: Pharmacokinetics
6/6
0
1
2
3
4
0 1 2 3 4 5 6
Lo
g10
CF
U
Time (month)
37Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. PLoS Med. 2006, 3, (11), 2131-2144.
6/6
6/6
6/6
6/66/6
6/6
1/6 0/6
1/6 4/5
0/60/6
O= OPC- 67683; R= rifampin; P= pyrazinamide; I= isoniazid; E= ethambutol
# of mice with CFU / total # mice
![Page 38: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/38.jpg)
OPC- 67683: Mechanism of Action
Same Mechanism of action as PA- 824
38
Yuan, Y.; Zhu, Y.; Crane, D. D.; Barry, C. E., III, Mol. Microbiol. 1998, 29, (6), 1449-1458. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Krelswirth, B. N.; Barry, C. E.; Baker, W. R. Nature 2000, 405, (6789), 962-966.
![Page 39: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/39.jpg)
TMC207 (R207910)
Phase II
Unique mechanism of action
Inhibits membrane-bound ATP synthase
Potentially inhibits drug-sensitive and drug-resistant strains
Reduced time to negative sputum culture
39
Diacon, A. H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.; Page-Shipp, L.; Pistorius, C.; Krause, R.; Bogoshi, M.; Churchyard, G.; Venter, A.; Allen, J.; Palomino, J. C.; De Marez, T.; van Heeswijk, R. P. G.; Lounis, N.; Meyvisch, P.; Verbeeck, J.; Parys, W.; de Beule, K.; Andries, K.; McNeeley, D. F. N. Engl. J. Med. 2009, 360, (23), 2397-2405.
![Page 40: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/40.jpg)
Synthesis of TMC207
40Van Gestel, J. F. E.; Guillemont, J. E. G.; Venet, M. G.; Poignet, H. J. J.; Decrane, L. F. B.; Vernier, D. F. J.; Odds, F. C. 2004-7026, 2005148581, 20041208, 2005.
![Page 41: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/41.jpg)
Synthesis of TMC207
41Van Gestel, J. F. E.; Guillemont, J. E. G.; Venet, M. G.; Poignet, H. J. J.; Decrane, L. F. B.; Vernier, D. F. J.; Odds, F. C. 2004-7026, 2005148581, 20041208, 2005.
![Page 42: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/42.jpg)
4
5
6
7
8
10
CF
U
Untreated (Day 0) 1 month 2 month
TMC207: Pharmacokinetic Studies
T = TMC207
20% 0% 0% 0%0%% of mice culture (-)
after 2 month
0
1
2
3
4
Untreated T R I P
log
10
Monotherapy
42
Ibrahim, M.; Andries, K.; Lounis, N.; Chauffour, A.; Truffot-Pernot, C.; Jarlier, V.; Veziris, N. Antimicrob. Agents Chemother. 2007, 51, 1011-1015.Andries, K.; Verhasselt, P.; Guillemont, J.; Goehlmann, H. W. H.; Neefs, J.-M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. Science 2005, 307, (5707), 223-227.
T = TMC207R = rifampinI = isoniazidP = pyrazinamide
![Page 43: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/43.jpg)
TMC207: Pharmacokinetic Studies
T = TMC2073
4
5
6
7
8
log
10
CF
U
Untreated (Day 0) 1 month 2 month
20% 100% 30% 20%0% 20% 0% 0%% of mice culture (-)
after 2 month
43
T = TMC207P = pyrazinamideR = rifampinI = isoniazid0
1
2
3log
Two- drug therapy
Ibrahim, M.; Andries, K.; Lounis, N.; Chauffour, A.; Truffot-Pernot, C.; Jarlier, V.; Veziris, N. Antimicrob. Agents Chemother. 2007, 51, 1011-1015.Andries, K.; Verhasselt, P.; Guillemont, J.; Goehlmann, H. W. H.; Neefs, J.-M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. Science 2005, 307, (5707), 223-227.
![Page 44: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/44.jpg)
TMC207: Pharmacokinetic Studies
T = TMC2073
4
5
6
7
8
log
10
CF
U
Untreated (Day 0) 1 month 2 month
20% 100% 70% 78%0% 20% 0%% of mice culture (-)
after 2 month
44
T = TMC207P = pyrazinamideR = rifampinI = isoniazid0
1
2
3log
Three- drug therapy
Ibrahim, M.; Andries, K.; Lounis, N.; Chauffour, A.; Truffot-Pernot, C.; Jarlier, V.; Veziris, N. Antimicrob. Agents Chemother. 2007, 51, 1011-1015.Andries, K.; Verhasselt, P.; Guillemont, J.; Goehlmann, H. W. H.; Neefs, J.-M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. Science 2005, 307, (5707), 223-227.
![Page 45: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/45.jpg)
Phase II Key Findings
TMC207 (N) Placebo (N)
Median Log10 CFU Count(Week 1)
4.7 (8) 5.2 (13)
(Week 2) 1.8 (9) 3.5 (11)
(Week 4) ~0 (6) 2.6 (12)
(Week 6) ~0 (5) 2.2 (11)
45
Diacon, A. H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.; Page-Shipp, L.; Pistorius, C.; Krause, R.; Bogoshi, M.; Churchyard, G.; Venter, A.; Allen, J.; Palomino, J. C.; De Marez, T.; van Heeswijk, R. P. G.; Lounis, N.; Meyvisch, P.; Verbeeck, J.; Parys, W.; de Beule, K.; Andries, K.; McNeeley, D. F. N. Engl. J. Med. 2009, 360, (23), 2397-2405.
(Week 6) ~0 (5) 2.2 (11)
(Week 8) ~0 (7) ~0 (7)
Side Effects
(Nausea)26% (23) 4% (24)
(+) to (-) culture in 8 weeks
48% (23)[10:21]
9% (24)[2:23]
![Page 46: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/46.jpg)
TMC207: Mechanism of Action
H2N
H
Arg-186
a-subunit
46Image taken from: http://www.biologie.uni-hamburg.de/b-online/e19/19d.htm.
O
O
H
Glu-61
c-subunit
![Page 47: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/47.jpg)
Inhibition of c-subunit of ATP synthase
TMC207: Mechanism of Action
47de Jonge, M. R.; Koymans, L. H. M.; Guillemont, J. E. G.; Koul, A.; Andries, K. Proteins: Struct.
Funct. Bioinf. 2007, 67, (4), 971-980.
![Page 48: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/48.jpg)
PA- 824 Activity against non-replicating
OPC-67683High efficacy in immunocompromised
In Summary
High efficacy in immunocompromised
TMC207Increased potency against multidrug resistant strains
All of the AboveActivity against drug-susceptible and resistant stains
48
![Page 49: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/49.jpg)
Although excellent promise,
If used incorrectly, resistance will develop
Understanding disease evolution
The Take Home Message
Better approach to treating a target disease
49
![Page 50: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/50.jpg)
Acknowledgements
Prof. Xuefei Huang
Prof. Babak Borhan
Group Members
Bo, Gopi, Mohammad, Dino, Gilbert, Hovig, Vivian
Medha, Ashley, Dennis, Steve
50
![Page 51: Novel Tuberculosis Drugs of the 21st Century Tuberculosis (TB) - “An infectious disease of humans and animals caused by the tubercle bacillus and characterized by the formation of](https://reader034.vdocuments.mx/reader034/viewer/2022050918/5af6d95f7f8b9a744490037c/html5/thumbnails/51.jpg)
Go State!
51
26 - 20Image from: http://scores.espn.go.com/ncf/photos?photoId=2347018&gameId=29276012713